BUZZ-Uniqure jumps after FDA vaccines chief Vinay Prasad to step down

Reuters03-07 07:18
BUZZ-Uniqure jumps after FDA vaccines chief Vinay Prasad to step down

** U.S.-listed shares of Dutch drugmaker UniQure UQ1.F, QURE.O rise 61% to $22.95 in extended trading

** The head of the U.S. Food and Drug Administration's vaccines and biologics unit, Dr. Vinay Prasad, will leave the agency at the end of April, FDA commissioner Marty Makary said on Friday

** More recently, Prasad's division at the FDA has been mired in a back and forth with Dutch drugmaker UniQure over its gene therapy for Huntington's disease

** Co is developing a gene therapy, AMT-130, for Huntington’s disease, a rare condition that affects motor function

** Makary says in a post on X that a successor will be named before Prasad’s departure

** Shares of some gene therapy developers also rose in extended trading, following the announcement

** Shares of Sarepta Therapeutics SRPT.O rises 6%, Capricor Therapeutics CAPR.O climbs 12%, Taysha Gene Therapies TSHA.O gains 1%

** UniQure rose 35.5% in 2025

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment